Potassium citrate

Identification

Summary

Potassium citrate is an agent used to manage renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones.

Brand Names
Cytra-K, Urocit-K
Generic Name
Potassium citrate
DrugBank Accession Number
DB09125
Background

Potassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. It is a white, hygroscopic crystalline powder. It is odorless with a saline taste. It contains 38.3% potassium by mass. In the monohydrate form it is highly hygroscopic and deliquescent. Potassium citrate is used to treat a kidney stone condition called renal tubular acidosis. Potassium Citrate is indicated also for the management of Hypocitraturic calcium oxalate nephrolithiasis.

Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Structure
Thumb
Weight
Average: 306.394
Monoisotopic: 305.89464697
Chemical Formula
C6H5K3O7
Synonyms
  • Potassium citrate anhydrous
  • Tripotassium citrate

Pharmacology

Indication

For the management of renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones.

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Potassium citrate induces changes in the urine which renders urine less susceptible to the formation of crystals and stones from salts e.g. calcium oxalate, calcium phosphate and uric acid. Increased citrate levels in the urine will make complexation with calcium which decrease the calcium ion activity and decrease the chance for the formation of calcium phosphate crystals. Citrate also inhibits the spontaneous nucleation of calcium oxalate and calcium phosphate.

Mechanism of action

After oral administration of potassium citrate, its metabolism yields alkaline load. Potassium Citrate therapy appears to increase urinary citrate mainly by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. In addition to raising urinary pH and citrate, Potassium Citrate increases urinary potassium by approximately the amount contained in the medication. In some patients, Potassium Citrate causes a transient reduction in urinary calcium.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Potassium Citrate is absorbed and the citrate is metabolised to bicarbonate.

Route of elimination

Urinary; less than 5% unchanged.

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

LD50 (dog): Intravenous 176 mg/kg.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirPotassium citrate may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Potassium citrate.
AcebutololAcebutolol may increase the hyperkalemic activities of Potassium citrate.
AceclofenacThe risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Potassium citrate.
AcemetacinThe therapeutic efficacy of Potassium citrate can be decreased when used in combination with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Acenocoumarol is combined with Potassium citrate.
AcetaminophenPotassium citrate may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Potassium citrate.
AclidiniumPotassium citrate may increase the excretion rate of Aclidinium which could result in a lower serum level and potentially a reduction in efficacy.
AcrivastinePotassium citrate may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
  • Take with food. Take potassium citrate within 30 minutes of eating to limit gastrointestinal irritation.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Potassium citrate monohydrateEE90ONI6FF6100-05-6PJAHUDTUZRZBKM-UHFFFAOYSA-K
Active Moieties
NameKindUNIICASInChI Key
Potassium cationionic295O53K15224203-36-9NPYPAHLBTDXSSS-UHFFFAOYSA-N
Citric acidunknownXF417D3PSL77-92-9KRKNYBCHXYNGOX-UHFFFAOYSA-N
Product Images
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Potassium CitrateTablet10 meq/1OralUpsher-Smith Laboratories, LLC2006-09-01Not applicableUS flag00245 0071 11 nlmimage10 f00df86f
Potassium CitrateTablet5 meq/1OralUpsher-Smith Laboratories, LLC2006-09-01Not applicableUS flag00245 0070 11 nlmimage10 234691d4
Urocit-KTablet, extended release5 meq/1OralMission Pharmacal Company1985-09-01Not applicableUS flag
Urocit-KTablet, extended release10 meq/1OralREMEDYREPACK INC.2016-12-272018-01-19US flag
Urocit-KTablet, extended release1080 mgOralMission Pharmacal Company2011-02-11Not applicableCanada flag
Urocit-KTablet, extended release15 meq/1OralMission Pharmacal Company2010-01-27Not applicableUS flag0178 061520180907 15195 1ux5bno
Urocit-KTablet, extended release15 meq/1OralPhysicians Total Care, Inc.2010-09-15Not applicableUS flag00178 0615 01 nlmimage10 581dac0d
Urocit-KTablet, extended release540 mgOralMission Pharmacal Company1995-01-01Not applicableCanada flag
Urocit-KTablet, extended release10 meq/1OralMission Pharmacal Company1992-09-01Not applicableUS flag
Urocit-KTablet, extended release10 meq/1OralPhysicians Total Care, Inc.2003-04-17Not applicableUS flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Potassium CitrateTablet, extended release10 meq/1OralActavis Pharma, Inc.2018-05-30Not applicableUS flag
Potassium CitrateTablet, extended release10 meq/1OralCamber Pharmaceuticals, Inc2021-02-15Not applicableUS flag
Potassium CitrateTablet, extended release10 meq/1OralANI Pharmaceuticals, Inc.2020-03-16Not applicableUS flag
Potassium CitrateTablet15 meq/1OralBiocomp Pharma, Inc.2013-12-23Not applicableUS flag44523 0415 01 nlmimage10 4a3ea535
Potassium CitrateTablet, extended release10 meq/1OralAscent Pharmaceuticals Inc2021-02-15Not applicableUS flag
Potassium CitrateTablet, extended release10 meq/1Oralbryant ranch prepack2018-05-30Not applicableUS flag
Potassium CitrateTablet, extended release15 meq/1Oralbryant ranch prepack2020-03-16Not applicableUS flag
Potassium CitrateTablet, extended release1080 mg/1OralMed-Health Pharma, LLC.2011-04-102012-04-25US flag
Potassium CitrateTablet, extended release10 meq/1OralAmerican Health Packaging2014-09-15Not applicableUS flag
Potassium CitrateTablet, extended release5 meq/1OralCadila Healthcare Limited2014-08-12Not applicableUS flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
MIXTURE POTASSIUM CITRATE BPCSyrupOralTERAPUTICS SDN BHD2020-09-08Not applicableMalaysia flag
Prime's Mixture Potassium CitrateSyrupOralPRIME PHARMACEUTICAL SDN. BHD.2020-09-08Not applicableMalaysia flag
UROCIT-K TABLET 10MEQ (1080MG)Tablet, extended releaseOralSOMEDICO SDN. BHD.2020-09-08Not applicableMalaysia flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
B6 Plus TabPotassium citrate (50 mg) + Magnesium oxide (50 mg) + Niacin (20 mg) + Pyridoxine hydrochloride (50 mg) + Riboflavin (2.4 mg) + Thiamine (10 mg)TabletOralVita Health Products Inc1979-12-312002-08-01Canada flag
DAILY-ONE 45 FILM TABLETPotassium citrate (18 mg) + Ascorbic acid (90 mg) + Beta carotene (2000 IU) + Biotin (0.06 mg) + Calcium phosphate, tribasic (100 mg) + Calcium phosphate, tribasic (50 mg) + Choline bitartrate (3.9 mg) + Chromium nicotinate (0.13 mg) + Cupric sulfate (2 mg) + Cyanocobalamin (0.015 mg) + Egg phospholipids (23 mg) + Ferrous fumarate (18 mg) + Folic acid (0.4 mg) + Inositol (3.9 mg) + Magnesium oxide (40 mg) + Manganese sulfate (3.5 mg) + Niacin (20 mg) + Pantothenic acid (20 mg) + Potassium Iodide (0.15 mg) + Pyridoxine hydrochloride (12 mg) + Riboflavin (10.2 mg) + Sodium selenite (0.07 mg) + Sodium molybdate (0.05 mg) + Thiamine hydrochloride (9 mg) + Vitamin A acetate (8000 IU) + Vitamin D (400 IU) + Vitamin E (60 IU) + Zinc gluconate (15 mg)Tablet, film coatedFERROSAN SAĞLIK ÜRÜN VE HİZMETLERİ A.Ş.2020-08-14Not applicableTurkey flag
Formula No. 2 Plus K LiqPotassium citrate (19.5 mg / mL) + Ascorbic acid (2 mg / mL)LiquidOralGolden Pride/Rawleigh1993-12-311996-09-30Canada flag
HIDRALITOSPotassium citrate monohydrate (216 mg) + Citric acid (369 mg) + D-glucose (2.5 g) + Sodium chloride (205 mg) + Sodium citrate dihydrate (98 mg)SolutionOralCOASPHARMA S.A.S. (ANTES COSMEPOP)2007-07-182019-03-26Colombia flag
HIDRAPLUS�45 SOLUCI�N ORAL.Potassium citrate monohydrate (0.203 g) + D-glucose (2.5 g) + Sodium chloride (0.205 g) + Sodium citrate dihydrate (0.098 g)SolutionOralTECNOFAR TQ S.A.S2008-10-082021-06-28Colombia flag
HIDRASOL 45MEQ CON ZINCPotassium citrate monohydrate (216 mg) + D-glucose monohydrate (2500 mg) + Sodium chloride (207.6 mg) + Sodium citrate dihydrate (94 mg) + Zinc gluconate (6.1 mg)SolutionOralQUIBI S.A. EN REESTRUCTURACION2014-07-04Not applicableColombia flag
hovid-Mixture Potassium CitratePotassium citrate (1 g/5ml) + Citric acid (200 mg/5ml)SolutionOralHovid Berhad2020-09-08Not applicableMalaysia flag
LytrenPotassium citrate (270 mg / 100 mL) + Citric acid (26 mg / 100 mL) + Dextrose, unspecified form (2 g / 100 mL) + Sodium chloride (263 mg / 100 mL) + Sodium citrate (49 mg / 100 mL)LiquidOralMead Johnson Nutritionals1985-12-312003-07-08Canada flag
Lytren Rhs LiqPotassium citrate (217 mg / 100 mL) + Citric acid (26.1 mg / 100 mL) + Sodium chloride (375 mg / 100 mL) + Sodium citrate (107 mg / 100 mL)LiquidOralMead Johnson Nutritionals1990-12-312000-09-11Canada flag
MENAPHASE FORMULA FILM TABLET, 90 ADETPotassium citrate (8.3 mg) + Ascorbic acid (42 mg) + Biotin (0.05 mg) + Calcium (167 mg) + Choline (3.1 mg) + Chromium (0.0217 mg) + Copper (0.33 mg) + Cyanocobalamin (0.0083 mg) + Ferrous gluconate (3 mg) + Folic acid (0.067 mg) + Inositol (3.1 mg) + Iodine (0.0025 mg) + Lecithin (18 mg) + Magnesium oxide (84 mg) + Manganese (0.6 mg) + Molybdenum (0.0083 mg) + Niacin (8.3 mg) + Calcium pantothenate (8.3 mg) + Phosphorus (35 mg) + Pyridoxine (16.7 mg) + Riboflavin (8.5 mg) + Selenium (0.0117 mg) + Thiamine (7.5 mg) + Vitamin A (833 IU) + Vitamin D (67 IU) + Vitamin E (67 IU) + Zinc (2.5 mg)TabletOralFERROSAN SAĞLIK ÜRÜN VE HİZMETLERİ A.Ş.2020-08-14Not applicableTurkey flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Cytra 3Potassium citrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate (500 mg/5mL)SyrupOralCypress Pharmaceuticals, Inc2008-07-292014-10-11US flag
Cytra 3Potassium citrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate (500 mg/5mL)SyrupOralPegasus Laboratories2006-05-052009-10-17US flag
Cytra-KPotassium citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralCypress Pharmaceuticals, Inc.2008-09-302014-10-11US flag
Cytra-K CrystalsPotassium citrate (3.3 g/1) + Citric acid monohydrate (1.002 g/1)Granule, for solutionOralCypress Pharmaceuticals, Inc.2003-05-01Not applicableUS flag
Potassium Citrate and Citric AcidPotassium citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralPharmaceutical Associates, Inc.1997-10-07Not applicableUS flag
Potassium Citrate Citric Acid CrystalsPotassium citrate (3.3 g/1) + Citric acid monohydrate (1.002 g/1)Granule, for solutionOralVirtus Pharmaceuticals LLC2014-06-132019-04-30US flag
Potassium Citrate-Citric AcidPotassium citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralMethod Pharmaceuticals2015-12-212016-03-03US flag
Potassium Citrate-Citric AcidPotassium citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralMethod Pharmaceuticals2014-10-202015-12-31US flag
Potassium Citrate-Sodium Citrate-Citric AcidPotassium citrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate dihydrate (500 mg/5mL)SolutionOralMethod Pharmaceuticals2014-10-202015-12-31US flag
Potassium Citrate-Sodium Citrate-Citric AcidPotassium citrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate dihydrate (500 mg/5mL)SolutionOralMethod Pharmaceuticals2015-12-212016-03-03US flag

Categories

ATC Codes
A12BA02 — Potassium citrate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Tricarboxylic acids and derivatives
Direct Parent
Tricarboxylic acids and derivatives
Alternative Parents
Tertiary alcohols / Carboxylic acid salts / Carboxylic acids / Organic potassium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Alcohol / Aliphatic acyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid salt / Hydrocarbon derivative / Organic alkali metal salt / Organic oxide / Organic oxygen compound / Organic potassium salt
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
potassium salt (CHEBI:64733)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
86R1NVR0HW
CAS number
866-84-2
InChI Key
QEEAPRPFLLJWCF-UHFFFAOYSA-K
InChI
InChI=1S/C6H8O7.3K/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3
IUPAC Name
tripotassium 2-hydroxypropane-1,2,3-tricarboxylate
SMILES
[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

References

General References
  1. Monograph [Link]
  2. safety data sheet [Link]
PubChem Compound
13344
PubChem Substance
310265041
ChemSpider
12775
RxNav
54993
ChEBI
64733
ChEMBL
CHEMBL1200458
Wikipedia
Potassium_citrate
FDA label
Download (81.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentBismuth / Helicobacter Pylori Infection / Malignant Neoplasm of Stomach1
4CompletedTreatmentBone Diseases, Metabolic / Postmenopausal Osteoporosis1
4CompletedTreatmentDuodenal Ulcer Due to Helicobacter Pylori1
4CompletedTreatmentDyspepsia / Peptic Ulcer1
4CompletedTreatmentEradication Therapy of Helicobacter Pylori1
4CompletedTreatmentFunctional Dyspepsia / Helicobacter Pylori / Peptic Ulcer1
4CompletedTreatmentFunctional Dyspepsia / Peptic Ulcer1
4CompletedTreatmentFunctional Dyspepsia / Scarred Peptic Ulcer1
4CompletedTreatmentHelicobacter Pylori Infection6
4CompletedTreatmentHelicobacter Pylori Treatment Failure1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Granule, effervescentOral
Injection, powder, for solutionIntramuscular
Injection, solutionIntramuscular
SuppositoryRectal
Tablet, effervescentOral
SyrupOral
SolutionOral
Granule, for solutionOral
Tablet, film coated
Powder, for solutionOral
GranuleOral2157.3 mg
SyrupOral
TabletOral
TabletOral
Tablet, extended releaseOral1080 mg/1
Tablet, extended releaseOral5 meq/1
Tablet, extended releaseOral540 mg/1
TabletOral10 meq/1
TabletOral15 meq/1
TabletOral5 meq/1
For solutionOral
LiquidOral
Tablet, extended releaseOral10 meq/1
Tablet, extended releaseOral15 meq/1
Tablet, extended releaseOral540 mg
Tablet, extended releaseOral
Tablet, extended releaseOral1080 mg
Syrup
SolutionNasal
TabletOral1080 mg
Tablet
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility39.4 mg/mLALOGPS
logP-0.7ALOGPS
logP-1.3ChemAxon
logS-0.89ALOGPS
pKa (Strongest Acidic)3.05ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area140.62 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity68.14 m3·mol-1ChemAxon
Polarizability14.23 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Drug created on September 23, 2015 16:41 / Updated on July 29, 2021 06:27